Key Insights

Highlights

Treatment Research

4 treatments under study, led by Dostarlimab

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05065021Phase 2Unknown

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Showing all 1 trials

Research Network

Common Treatments

  • Dostarlimab1
  • Niraparib1
  • Bevacizumab1
  • Paclitaxel1

Active Sponsors

  • University Health Network, Toronto1
  • GSK1

Top Investigators

Related Conditions

  • Fallopian Tube Cancer1
  • Ovarian Cancer1
  • High Grade Serous Cancer1
  • Primary Peritoneal Cancer1

Activity Timeline